RECORDATI: ACQUISITION OF RIGHTS TO ASTRAZENECA'S METOPROLOL BASED TREATMENTS IN EUROPE COMPLETED

Milan, 3 July 2017 - Recordati announced the successful conclusion* of the agreement with AstraZeneca for the acquisition of the rights to Seloken®/Seloken® ZOK (metoprolol succinate) and associated Logimax® fixed dose combination (metoprolol succinate and felodipine) treatments in Europe. Metoprolol succinate is a beta-blocker for the control of hypertension, angina and heart failure. The consideration for the acquisition of the assets of $ 290 million (€ 258 million) was paid at the closing.

Metoprolol is a widely used drug in all European countries and the market position achieved by the AstraZeneca brands will enable Recordati to reinforce its product portfolios in a number of European countries, in particular in Poland, France and Germany. Furthermore, existing sales of the metoprolol brands will provide the base to enter new markets and thus complete the group's European geographical footprint. Recordati has significant experience in the marketing of treatments for cardiovascular disease with an existing portfolio of medicines for hypertension and related conditions as well as an established salesforce across European markets.

* With the exception of Romania, which is subject to separate closing

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, other Central and Eastern European countries, Turkey, North Africa, the United States of America, Canada, Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2016 was € 1,153.9 million, operating income was € 327.4 million and net income was €

237.4 million.

For further information:

Recordati website: www.recordati.com

Investor Relations Media Relations

Marianne Tatschke Studio Noris Morano

(39)0248787393 (39)0276004736, (39)0276004745

e-mail: investorelations@recordati.it e-mail: norismorano@studionorismorano.com

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale

VIA M. CIVITALI, 1 CAPITALE SOCIALE € 26.140.644,50 I.V.

20148 MILANO, ITALIA REG. IMP. MILANO N. 00748210150

TEL. (39) 0248787.1 CODICE FISCALE/P.IVA 007482210150

FAX (39) 0240073747 R.E.A. MILANO N. 401832

Recordati S.p.A. published this content on 03 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 03 July 2017 07:54:06 UTC.

Original documenthttp://www.recordati.it/resources/Pubblicazione/___de7f1eb486954004bdfdff2bd91ebf24_/az-metoprolol-closing-en.pdf

Public permalinkhttp://www.publicnow.com/view/3B35C181B6082110686F0681B6646207338F07F5